Seeking Alpha

Relief for long-suffering investors in Mela Sciences (MELA +4.1%) may soon be at hand, Barron's...

Relief for long-suffering investors in Mela Sciences (MELA +4.1%) may soon be at hand, Barron's writes. The maker of a promising device for diagnosis cancer said last week that the FDA had finally issued an "approvals letter," which analysts say should help it resolve all remaining issues before a final vote.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector